Literature DB >> 24461770

Long-term prognostic value of mitral regurgitation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Manuel López-Pérez1, Rodrigo Estévez-Loureiro2, Angela López-Sainz1, David Couto-Mallón1, María Rita Soler-Martin1, Alberto Bouzas-Mosquera1, Jesús Peteiro1, Gonzalo Barge-Caballero1, Oscar Prada-Delgado1, Eduardo Barge-Caballero1, Jorge Salgado-Fernández1, Ramón Calviño-Santos1, José Manuel Vázquez-Rodríguez1, Pablo Piñón-Esteban1, Guillermo Aldama-López1, Nicolás Vázquez-González1, Alfonso Castro-Beiras1.   

Abstract

The presence of mitral regurgitation (MR) is associated with an impaired prognosis in patients with ischemic heart disease. However, data with regard to the impact of this condition in patients with ST-segment elevation myocardial infarction (STEMI) treated by means of primary percutaneous coronary intervention (PPCI) are lacking. Our aim was to assess the effect of MR in the long-term prognosis of patients with STEMI after PPCI. We analyzed a prospective registry of 1,868 patients (mean age 62 ± 13 years, 79.9% men) with STEMI treated by PPCI in our center from January 2006 to December 2010. Our primary outcome was the composite end point of all-cause mortality or admission due to heart failure during follow-up. After exclusions, 1,036 patients remained for the final analysis. Moderate or severe MR was detected in 119 patients (11.5%). Those with more severe MR were more frequently women (p <0.001), older (p <0.001), and with lower ejection fraction (p <0.001). After a median follow-up of 2.8 years (1.7 to 4.3), a total of 139 patients (13.4%) experienced our primary end point. There was an association between the unfavorable combined event and the degree of MR (p <0.001). After adjustment for relevant confounders, moderate or severe MR remained as an independent predictor of the combined primary end point (adjusted hazard ratio [HR] 3.14, 95% confidence interval [CI] 1.57 to 6.27) and each event separately (adjusted HR death 3.1, 95% CI 1.34 to 7.2; adjusted HR heart failure 3.3, 95% CI 1.16 to 9.4). In conclusion, moderate or severe MR detected early with echocardiography was independently associated with a worse long-term prognosis in patients with STEMI treated with PPCI.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24461770     DOI: 10.1016/j.amjcard.2013.11.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis.

Authors:  Anna Sannino; Robert L Smith; Gabriele G Schiattarella; Bruno Trimarco; Giovanni Esposito; Paul A Grayburn
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

2.  Outcomes of ischaemic mitral regurgitation in anterior versus inferior ST elevation myocardial infarction.

Authors:  Amgad Mentias; Mohammad Q Raza; Amr F Barakat; Elizabeth Hill; Dalia Youssef; Amar Krishnaswamy; Milind Y Desai; Brian Griffin; Stephen Ellis; Venu Menon; E Murat Tuzcu; Samir R Kapadia
Journal:  Open Heart       Date:  2016-11-10

3.  Myocardial infarction patients referred to the primary care physician after 1‑year treatment according to a guideline-based protocol have a good prognosis.

Authors:  M C Bodde; N E van Hattem; R Abou; B J A Mertens; H J van Duijn; M E Numans; J J Bax; M J Schalij; J W Jukema
Journal:  Neth Heart J       Date:  2019-11       Impact factor: 2.380

4.  Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period.

Authors:  Leor Perl; Tamir Bental; Katia Orvin; Hana Vaknin-Assa; Gabriel Greenberg; Pablo Codner; Yaron Shapira; Mordehay Vaturi; Alexander Sagie; Ran Kornowski
Journal:  Front Cardiovasc Med       Date:  2022-01-13

Review 5.  Percutaneous mitral valve repair in patients developing severe mitral regurgitation early after an acute myocardial infarction: A review.

Authors:  Rodrigo Estévez-Loureiro; Marta Tavares Da Silva; José Antonio Baz-Alonso; Berenice Caneiro-Queija; Manuel Barreiro-Pérez; Francisco Calvo-Iglesias; Rocio González-Ferreiro; Luis Puga; Miguel Piñón; Andrés Íñiguez-Romo
Journal:  Front Cardiovasc Med       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.